VitaStem by Aubrai
VitaSTEM — The first AI-enabled longevity project and inaugural IP-Token launched by Aubrai, VitaDAO’s decentralized scientific agent. After six months of deep research on public and proprietary single-cell RNA-seq and multi-omics datasets, our scientific research team analyzed more than 850,000 human hematopoietic stem cell transcriptomes from donors aged 23–91 (both male and female). This effort uncovered 100+ high-potential rejuvenation target genes and revealed critical drivers of decline such as RhoA hyperactivation, CD38 upregulation, and CCR9 downregulation. Rather than treating HSC aging as a single defect, Aubrai recognized it as convergent damage across interconnected systems, generating a comprehensive multi-modal, five-phase rejuvenation protocol targeting transcriptional stress, metabolic dysfunction, and epigenetic drift in parallel. The agent shortlisted target genes using insights from thousands of peer-reviewed publications and private data and also optimized experimental protocols to guide in vitro and upcoming pre-clinical testing. For the first time, human researchers and AI Agents collaborate as co-scientists in the creation of pioneering scientific IP.
Community Sentiment
How do you feel about this ipt?
1. Pledging BioXP
Your final token allocation is determined by your BioXP pledge relative to the total BioXP pledged by other participants.
Over-pledging increases your chances of obtaining the max allocation (0.5% of the total supply).
If the launch succeeds, only the BioXP used for your final allocation are burnt, and you are refunded the rest.
2. Committing $BIO
The $BIO you commit during the fundraising will be used to purchase your final token allocation.
The price of the token is fix (1 $BIO = X $AGENT).
3. Claiming your tokens
Once the launch has succeeded, claim your purchased tokens on this page (check the Community Announcements).
Any refunded $BIO will be claimable in your Portfolio page.
Project
Market Overview
Summary
We analyzed 850,000 single-cell transcriptomes of hematopoietic stem cells (HSCs) across ages and identified lead target genes for rejuvenation. This proposal aims to validate these targets in vitro using RNA-based interventions and small molecules.
Problem
Aging drives HSC dysfunction, impairing the regeneration of blood and immune cells. Current treatments lack strategies to restore youthful HSC function. Precise targets for rejuvenation remain unvalidated despite advances in scRNA-seq.
Impact
Validated interventions could reverse HSC aging, restoring regenerative capacity and immune balance. This work opens a new path in regenerative medicine, enabling multi-modal strategies to improve healthspan and combat age-related decline.
Market Overview
Summary
We analyzed 850,000 single-cell transcriptomes of hematopoietic stem cells (HSCs) across ages and identified lead target genes for rejuvenation. This proposal aims to validate these targets in vitro using RNA-based interventions and small molecules.
Problem
Aging drives HSC dysfunction, impairing the regeneration of blood and immune cells. Current treatments lack strategies to restore youthful HSC function. Precise targets for rejuvenation remain unvalidated despite advances in scRNA-seq.
Impact
Validated interventions could reverse HSC aging, restoring regenerative capacity and immune balance. This work opens a new path in regenerative medicine, enabling multi-modal strategies to improve healthspan and combat age-related decline.
Ashish Rajput, Ph.D.
On a mission is to catalyze life science innovations to enhance human longevity and health-span. Inspired to cure Aging and age-related diseases such as cancer, Alzheimer's and other neurodegenerative diseases in the current generation lifetime. Currently investigating the links between Aging and cancer at the cellular and molecular level. Taking academic and entrepreneurial routes to progress science and its benefits to society.
In-silico study
Identification of genes which have potential for in-situ HSC rejuvenation by human single cell RNA-seq data analysis
In-vitro validation
Validate shortlisted target genes/proteins in in-vitro HSC cells
Intervention studies
Perform gene activation/ inhibition to confirm efficacy of the intervention in human Hematopoietic stem cells
Small-molecule/drug intervention
Identify small molecules that can activate/inhibit to mimic targeted interventions
Pre-clinical testing
Complete additional tests such as Toxicity studies, effective dose studies, etc., in mice and platforms such as human-on-a-chip
A reference model of circulating hematopoietic stem cells across the lifespan with applications to diagnostics
https://www.nature.com/articles/s41591-025-03716-5
Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution
https://elifesciences.org/articles/79363
Single-cell Transcriptional Atlas of Human Hematopoiesis Reveals Genetic and Hierarchy-Based Determinants of Aberrant AML Differentiation
https://aacrjournals.org/bloodcancerdiscov/article/6/4/307/763153/Single-cell-Transcriptional-Atlas-of-Human
Single-cell RNA sequencing to track novel perspectives in HSC heterogeneity
https://stemcellres.biomedcentral.com/articles/10.1186/s13287-022-02718-1
Single-cell RNA-seq reveals changes in cell cycle and differentiation programs upon aging of hematopoietic stem cells
https://genome.cshlp.org/content/25/12/1860.full
Single Cell Transcriptomics to Understand HSC Heterogeneity and Its Evolution upon Aging
https://www.mdpi.com/2073-4409/11/19/3125
Tokenomics
10,000,000
Total SupplyIgnition Sale | 15% |
Liquidity | 10% |
Concentrated Liquidity | 10% |
VitaDAO | 20% |
Aubrai Agent | 20% |
Researcher | 10% |
Bio Protocol | 2% |
Project Treasury | 13% |
10,000,000
Total SupplyIgnition Sale | 15% |
Liquidity | 10% |
Concentrated Liquidity | 10% |
VitaDAO | 20% |
Aubrai Agent | 20% |
Researcher | 10% |
Bio Protocol | 2% |
Project Treasury | 13% |
Community
No announcements yet
Come back at a later point
Stay up to date
Get the latest community updates and find out about upcoming VitaStem by Aubrai developments
